Until Ralph Steinman discovered DCs, the innate and adaptive systems had been considered separate entities for nearly a century. Innate immunity involved Elie Metchnikoff's phagocytes, particularly macrophages that internalize and kill microbes. Paul Ehrlich's adaptive immunity involved lymphocytes that produce the antibodies that are so often used for clinical benefit. A new dimension to Ehrlich's work was first described in the 1940s by Merrill Chase, a researcher at the Rockefeller Institute who showed that lymphocytes, rather than antibodies, bring about adaptive immunity. It is now known that this cell-mediated immunity involves T lymphocytes in many different helper, cytotoxic, and suppressor forms, and that they are all controlled by DCs. Ralph's discovery thus provided the missing link between innate and adaptive immunity. DCs are essential for understanding how the immune system works during health and how diseases develop. They are unavoidable targets for identifying new preventions and therapies.
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Discovery
=========

During his medical training, Ralph was challenged to learn how an antigen provokes an immune response. He recognized that MacFarlane Burnet's clonal selection theory could not account for how the body responds to substances---both foreign and self---by generating a diverse repertoire of immune cells, each with a single, distinct antibody as its receptor ([@bib2]). Because clonal selection could not be initiated by adding foreign proteins to lymphocytes, it was thought that mysterious "accessory" cells were also required to induce immunity. One idea was that accessory cells were macrophages.

The story of DCs began in 1970, when Ralph joined the Rockefeller University as a postdoctoral fellow in the laboratory of Zanvil (Zan) Cohn, the founder of modern macrophage biology. This was an ideal place to directly test whether macrophages would trap intact antigens and present them to lymphocytes. The laboratory was founded by the premier microbiologist René Dubos, who recognized the need to study the host during infection. He had been the ideal mentor for James Hirsch and Zan, two physicians devoted to infectious disease, who pursued elegant careers with phagocytes. Dubos, Hirsch, and Cohn were all editors of this journal.

Ralph's initial research focused on endocytosis of proteins in macrophages. But when he was unable to find reservoirs of intact antigen on peritoneal macrophages, he turned to the spleen to see if this organ might harbor cells responsible for generating immunity ([@bib35]).

Ralph and Zan discovered DCs in 1973. Looking through a phase contrast microscope, they encountered a population of cells from the spleen that had never been seen before and did not look like macrophages. The cells were elongated with unusual stellate, or treelike, processes that were constantly forming and retracting. Ralph named them dendritic cells (from the Greek word *dendreon* for tree; [@bib36], [@bib37]).

Purification
============

It took nearly 5 years to get pure populations of DCs and to compare their functions with those of other cell types. DCs were rare (\<1% of mouse spleen cells), and their only unique markers were their unusual shape and movement. Fortunately, George Palade, Phil Siekevitz, David Sabatini, Günter Blobel, and Christian de Duve---who were in the process of inventing modern cell biology---were neighbors of the Cohn laboratory in Rockefeller's Bronk Building. The de Duve laboratory's expertise in density gradient centrifugation for subcellular fractionation was key to Ralph's purification methods. The elegant and ingenious steps Ralph worked out started with centrifuging spleen cells on a bovine serum albumin gradient, on which semipurified DCs rose to the top. He then placed this fraction on glass for one hour, delicately washed away all but the DCs and some macrophages, and cultured these cells overnight to let the DCs detach from the culture dish and float into suspension. The lingering few macrophages were removed by adding antibody-coated sheep red blood cells and centrifuging them out ([@bib41]). This procedure was laborious, and the DC yield was poor. As a result, few laboratories attempted to reproduce it or to work with DCs for many years. After an antibody was developed to CD11c, an antigen expressed by DCs, activated monocytes, and NK cells, purification became routine ([@bib26]).

Mixed leukocyte reaction
========================

Functional studies on DCs began once Ralph had pure DC populations. He noted that DCs expressed high levels of MHC proteins. Therefore, along with Maggi Witmer-Pack, he evaluated their capacity to stimulate the mixed leukocyte reaction (MLR). This T cell reaction had been used for 15 years to detect differences in MHC antigens between potential donors and recipients of organ transplants. At the time, it was termed mixed lymphocyte reaction because it was thought that B cells from the potential transplant donor triggered the division of T cells of the potential transplant recipient. Ralph showed that the newly identified DCs were 100 times more potent than bulk spleen cells at inciting the MLR, and that antigen-bearing B cells and macrophages contributed little to initiating the reaction. The DCs were converting transplantation antigens into "immunogens" capable of eliciting cell and organ rejection. In 1978, Ralph predicted that DCs would "prove to be a critical accessory cell required in the generation of many immune responses" ([@bib40]). However, this interpretation was not accepted by most immunologists because of the unusual features of the MLR in comparison to other immune responses. For example, the antigens responsible for initiating the MLR were not well defined, and vigorous in vitro responses apparently required no priming.

Antigen presentation
====================

The next few years were very productive, and DCs were quickly shown to effectively present antigens to T cells. Michel Nussenzweig, the first student to work on DCs, showed that DCs capture antigens and present them to cytolytic T lymphocytes. Michel modified syngeneic thymocytes with trinitrophenyl and showed that DCs could capture, process, and present the antigen to produce MHC-restricted cytolytic T lymphocytes ([@bib28]). Michel also developed 33D1, the first DC-specific monoclonal antibody ([@bib29]). Although 20 years passed before the antigen recognized by 33D1 was characterized at the molecular level ([@bib7]), 33D1 was important because it revealed the first molecular distinction between DCs and all other immune cell types. Michel and Ralph used this monoclonal antibody to selectively deplete DCs, but not monocytes, from spleen suspensions to show that the DC was the primary stimulator of the MLR in bulk spleen ([@bib42]).

Another student, Wes van Voorhis, identified DCs in human blood ([@bib48]) and developed a monoclonal antibody that killed monocytes, but not DCs. These experiments were important because they provided evidence that DCs also existed in humans and set the stage for later immunization experiments ([@bib11]).

Ralph and Kayo Inaba demonstrated a role for DCs in stimulating naive B cells to produce antibodies capable of binding sheep red blood cells and protein antigens. They showed that once helper T cells had been activated by DCs, the T cells could interact efficiently with antigen-presenting B cells to drive B cell clonal expansion and antibody production ([@bib9], [@bib10]; [@bib12]). They noted that antigen-reactive T cells clustered on the surfaces of the very small number of DCs, typically 1% or less of the total cells, in their experimental systems. Analyzing these T cell--DC clusters, they showed that DCs provide the "microenvironment" for T cell activation and generation of cellular immunity ([@bib14]).

In all of these systems, small numbers of DCs would elicit a T cell response, whereas much larger numbers of other cell types failed to do so. These experiments led to the realization that there are two stages to every immune response. The first is an afferent stage during which DCs stimulate the growth and differentiation of rare quiescent precursors of antigen-specific helper and cytolytic T cells. The second stage is an efferent limb during which T cells that have been activated by DCs divide in response to encounter with antigens that have been processed and presented by other cells, including B cells and macrophages. This second stage yields large numbers of effector T cells that participate in many immunological reactions ([@bib38]; [@bib34]). Together, these afferent and efferent limbs solve the conundrum of how rare antigen-specific lymphocytes are selected and mobilized to bring about vigorous specific responses.

Maturation
==========

To gain information about DCs in nonlymphoid tissues, Ralph turned to the epidermal Langerhans cells, which were also known to express high levels of MHC class II proteins. With Gerold Schuler, Niki Romani, and Kayo, Ralph found that Langerhans cells needed to differentiate, or mature, to become typical immune stimulatory cells ([@bib32]; [@bib13]; [@bib30]). Although Langerhans cells were later shown to have a separate cellular origin from that of DCs ([@bib25]), they served as a model to understand DC function. Ralph and his colleagues discovered that maturing cells exhibited different functional attributes during different periods of time. The first function, antigen capture and presentation, is exhibited by immature DCs. The second function, accessory or co-stimulatory activity, is mediated by mature DCs. Although all DCs process and present antigens, the maturation of DCs determines the type and quality of the immune response that will result from recognition of DC-presented antigens by T cells. There was also evidence that the environment in which DCs mature exerts a major influence on the form of adaptive immunity they promote. Thus, maturation of DCs serves as the critical link between innate and adaptive T cell--dependent immunity.

Growing DCs
===========

Early research on DCs was limited by the need to isolate these scarce cells from primary tissues. During the early 1990s, Ralph and colleagues identified methods for stimulating bone marrow cells to grow and differentiate in vitro into cells that displayed many of the phenotypic characteristics of DCs ([@bib16],[@bib17], [@bib18]; [@bib31]). By 2000, other investigators had discovered that Flt-3L, a hematopoietin that causes a dramatic 10--15-fold expansion of DCs in mice and in humans, can be used to grow authentic DCs in vitro. Once methods to generate large numbers of DCs became available, scientists could more easily study their immunizing properties. This development triggered a major expansion in research and greatly accelerated the pace of discovery.

Pursuing the concept that DCs are "nature's adjuvant," Ralph's group incubated maturing DCs with antigens in vitro and injected these cells into mice and, eventually, humans. The DCs stimulated T cell growth, and the expanded T cells recognized the specific antigens presented on the MHC products of the injected DCs ([@bib15]). These included microbial antigens in mice ([@bib19]) and model antigens in humans ([@bib5]). Prior to these discoveries, research on antigen presentation had emphasized tissue culture systems and used previously activated lymphocytes or cloned lymphocyte lines. With DCs, Ralph took the problem into immunologically intact mice and humans. By showing that DCs initiated immunity specific for the antigens they had captured, he justified using these cells to develop immunotherapeutic strategies.
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Endocytosis
===========

Ralph had assumed that splenic and skin DCs were fully ready to initiate immunity because of their high content of MHC II molecules. But when former Cohn laboratory member Ira Mellman and colleagues at Yale brought their expertise in cellular molecular biology to the DC field, they found that the MHC II proteins were mostly sequestered within the endocytic system of developing monocyte-derived DCs in vitro ([@bib44]). They proposed that this adaptation allows DCs to efficiently capture, process, and present antigens by preventing the complete catabolism of protein antigens ([@bib20]). By allowing peptide--MHC II complexes to form inside the endocytic system, DCs optimized their subsequent display at the cell surface ([@bib47]). The regulation and composition of the endocytic system points to a hallmark difference between DCs and macrophages. Whereas macrophages are specialized for continual antigen scavenging and destruction, DCs process antigen in a manner that generates the peptides that bind to different types of antigen-presenting molecules.

Ralph's studies with Michel on endocytic receptors expressed by DCs introduced yet another field of study: how to increase the immunogenicity of proteins by exploiting specific pathways for antigen uptake. The research began with biomedical student William Swiggard, who isolated DEC-205 (also called CD205; [@bib43]). Wanping Jiang, a postdoctoral fellow in Michel's laboratory, cloned the gene and showed that it encoded an endocytic receptor, the first such receptor identified on DCs in situ ([@bib22]). By incorporating antigens into monoclonal antibodies specific for DEC-205 and administering these antibodies to living animals, Daniel Hawiger, a student in Michel's laboratory, first showed that targeting antigens to DCs increased the efficiency of presentation by 100-fold ([@bib8]). Although the potency of DCs after antigen capture had been emphasized in the past, Ralph and Michel's work on antigen handling revealed that this function of DCs can be dramatically improved in intact animals.

Immune tolerance
================

Beginning in 2000, in close collaboration with Michel and Hawiger, Ralph uncovered roles for DCs in controlling immune tolerance ([@bib8]; [@bib39]). To analyze tolerance, Ralph took an approach first suggested by their discovery that immature DCs induce antigen-specific tolerance in humans ([@bib6]). Ralph studied two forms of antigen. One consisted of peptides and proteins incorporated into antibodies that recognize DEC-205, which is expressed on DCs in lymphoid tissues ([@bib8]). The other consisted of antigen within dying cells ([@bib21]; [@bib23]). When antigens were attached to anti--DEC-205, and thus targeted directly to immature DCs in vivo, in the absence of inflammatory stimuli that promote DC maturation, the antigens were processed and recognized by T cells but the T cells were tolerized in response. In contrast, delivery of a maturation stimulus together with the same targeted antigen produced long-lived immunity involving both helper and cytolytic T cells ([@bib8]; [@bib24]).

In addition to the classical pathway of clonal deletion, the regulatory T cell, particularly the variety programmed by the protein Foxp3, is a powerful mechanism of tolerance. In this issue of the journal, a paper by a postdoctoral fellow in Ralph's laboratory (Sela et al.) describes a way to use DCs to generate antigen-specific T reg cells capable of preventing graft versus host disease in mice.

Whereas inducing tolerance in fully developed lymphocytes formerly required high doses of nontargeted antigens and met with limited success, the targeted delivery of antigen to DCs more efficiently and specifically silenced the immune system.

DC-based vaccines
=================

From the beginning, Ralph planned to take DCs into medicine. His deep insights into the biology of DCs and his interest in the control of immunity led him to explore two novel approaches to stimulate innate immunity.

One strategy was an active immunization against advanced cancer. Madhav Dhodapkar, Ralph, and others developed ways to remove DCs from a patient, charge them with specific antigens, and deliver them back into the patient ([@bib4]). This approach, resulting in expanded and sustained T cell responses, recently approved by the US Food and Drug Administration, is now being used by many other laboratories.

The other vaccine strategy harnesses the major features of DCs---location, presentation, maturation, and formation of subsets---in situ. It involves engineering disease-relevant antigens into monoclonal antibodies and targeting them to particular DC-specific receptors. This approach, based on the work of [@bib8], is currently being applied to malaria, tuberculosis, *Leishmania*, cancer, and AIDS. The resulting T cell--mediated immune response to targeted antigens, relative to nontargeted antigens, is greater in efficacy, higher in magnitude, and associated with protection ([@bib1]; [@bib45], [@bib46]; [@bib27]).

A critical and separate issue in targeting vaccine proteins is to incorporate a stimulus or adjuvant to incite DC maturation. A paper in this issue, by Caskey et al. of the Rockefeller Hospital, together with Rafick Sékaly and his colleagues in Port St. Lucie, shows that in healthy humans the adjuvant double-stranded RNA (poly ICLC) stimulated a broad innate immune response mimicking that induced by a live viral vaccine.

Ralph was that rare scientist who lived through a period in which his endeavors came to fruition. He experienced a revolution in immunology and both performed and witnessed work that explained how DCs provide the physiological means to initiate clonal expansion, bring about tolerance, differentiate lymphocytes into disease-fighting cells, and develop memory, each in an antigen-specific manner. Ralph was excited when he found novel cells in 1973, and he died convinced that these cells had become a novel force in medicine.

Michel Nussenzweig, Svetlana Mojsov, and Maggi Witmer-Pack made valuable contributions to this manuscript.
